{
    "clinical_study": {
        "@rank": "117770", 
        "arm_group": [
            {
                "arm_group_label": "2 days Ivermectin", 
                "arm_group_type": "Experimental", 
                "description": "Ivermectin 200 - 400 \u00b5g/kg once daily for 2 days"
            }, 
            {
                "arm_group_label": "3 days Ivermectin", 
                "arm_group_type": "Experimental", 
                "description": "Ivermectin 200-400 \u00b5g/kg once daily for 3 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a  Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and\n      Safety of Ivermectin in Children and Adult patients with Dengue Infection."
        }, 
        "brief_title": "Efficacy and Safety of Ivermectin Against Dengue Infection", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Dengue Fever", 
        "condition_browse": {
            "mesh_term": [
                "Dengue", 
                "Dengue Hemorrhagic Fever"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with confirmed dengue infection who meet all inclusion and exclusion criteria will\n      be enrolled in the study and admitted in the hospital. Patients will be randomly assigned in\n      a pre-specified ratio of 1:1:1 to one of the following study groups: ivermectin 200-400\n      \u00b5g/kg single daily dose for 2 days, ivermectin 200-400 \u00b5g/kg single daily dose for 3 days,\n      or placebo. Tablets of ivermectin or placebo will be administered for 3 days. Clinical exam\n      will be performed daily during hospitalization and blood samples will be collected for\n      hematology, clinical chemistry, serology, viral load and quantitative nonstructural 1 (NS1)\n      antigen. Safety assessment will be conducted during admission. Patients will be discharged\n      one day after fever subsidence and will be asked to return 2 weeks after first dose of study\n      medication for safety assessment and blood sampling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults ages of 15 or greater.\n\n          -  History or presence of fever (temperature > 38\u00b0C) of \u2264 72 hr duration.\n\n          -  Clinical suspicion of dengue infection such as high fever without an evidence or\n             suspected focus of infection on clinical examination.\n\n          -  Positive NS 1 strip assay\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormal laboratory results which are deemed to be\n             unassociated with dengue infection\n\n          -  Clinical evidence or a history of significant respiratory, metabolic, renal, hepatic,\n             hematologic or chronic diseases\n\n          -  History of autoimmune, immune dysfunction disorder or taking warfarin\n\n          -  Clinical suspicion of any bacterial infection\n\n          -  Pregnancy and lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045069", 
            "org_study_id": "ESIDEN"
        }, 
        "intervention": [
            {
                "arm_group_label": "2 days Ivermectin", 
                "description": "200-400 \u00b5g/kg once daily for 2 days and placebo once daily at D3", 
                "intervention_name": "2 days Ivermectin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Mectizan", 
                    "Ivomec", 
                    "Stromectol"
                ]
            }, 
            {
                "arm_group_label": "3 days Ivermectin", 
                "description": "200 -400 \u00b5g/kg once daily for 3 days", 
                "intervention_name": "3 days Ivermectin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo once daily for 3 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ivermectin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "contact": {
                "email": "nasikarn@gmail.com", 
                "last_name": "Nasikarn Angkasekwinai, MD", 
                "phone": "66818708766"
            }, 
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10700"
                }, 
                "name": "Faculty of Medicine Siriraj Hospital, Mahidol University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection", 
        "overall_contact": {
            "email": "ysuputtamongkol@gmail.com", 
            "last_name": "Yupin Supputamonkol, MD.", 
            "phone": "6681-754-5573"
        }, 
        "overall_contact_backup": {
            "email": "panisadee.avi@mahidol.ac.th", 
            "last_name": "Panisadee Avirutnan, MD, PhD.", 
            "phone": "6681-895-0019"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ministry of Public Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to resolution of viremia", 
            "safety_issue": "No", 
            "time_frame": "Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045069"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to clearance of NS1 antigen", 
                "safety_issue": "No", 
                "time_frame": "Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first."
            }, 
            {
                "measure": "Time of subsidence of fever", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until  fever subsides"
            }
        ], 
        "source": "Mahidol University", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, Thailand", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mahidol University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}